ARK Invest's position in SLGL, updated every trading day. Data as of 2026-11-12.
| Fund | Shares | Value | Weight | Rank |
|---|---|---|---|---|
| IZRL | 28,755 | $1.6M | 1.35% | #56 |
| Trade day | Fund | Side | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-11-12 | IZRL | Sell | Trimmed | 520 | $29K |
| 2026-10-15 | IZRL | Buy | Added | 1,883 | $129K |
| 2026-08-26 | IZRL | Sell | Trimmed | 170 | $14K |
| 2026-07-16 | IZRL | Buy | New position | 28,318 | $2.2M |
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of…
See SLGL's full ARK history since 2024, ARK's estimated cost basis, the conviction score and buy/sell alerts.
Open SLGL on FundWake →Data comes from ARK Invest's public daily holdings and trade files. FundWake is not affiliated with ARK Invest. Nothing here is investment advice.